BACE-1 Inhibitors: From Recent Single-Target Molecules to Multitarget Compounds for Alzheimer's Disease

Topic: Drug trials: efficacy and safety

The amyloid hypothesis has long been the central dogma in drug discovery for Alzheimer's disease (AD), leading to many small-molecule and biological drug candidates. One major target has been the β-site amyloid-precursor-protein-cleaving enzyme 1 (BACE-1), with many big pharma companies expending great resources in the search for BACE-1 inhibitors. The lack of efficacy of verubecestat in mild-to-moderate AD raises important questions about the timing of intervention with BACE-1 inhibitors, and anti-amyloid therapies in general, in AD treatment. It also suggests new possibilities for discovering BACE-1-targeted compounds with more complex mechanisms of actions and improved efficacy. Herein, we review the major advances in BACE-1 drug discovery, from single-target small molecule inhibitors to multitarget compounds. We discuss these compounds as innovative tools for better understanding the complexity of AD and for identifying efficacious drug candidates to treat this devastating disease.

Key findings

• One major target has been the β-site amyloid-precursor-protein-cleaving enzyme 1 (BACE-1), with many big pharma companies expending great resources in the search for BACE-1 inhibitors.
• The lack of efficacy of verubecestat in mild-to-moderate AD raises important questions about the timing of intervention with BACE-1 inhibitors, and anti-amyloid therapies in general, in AD treatment.
• It also suggests new possibilities for discovering BACE-1-targeted compounds with more complex mechanisms of actions and improved efficacy.
• Herein, we review the major advances in BACE-1 drug discovery, from single-target small molecule inhibitors to multitarget compounds.
• We discuss these compounds as innovative tools for better understanding the complexity of AD and for identifying efficacious drug candidates to treat this devastating disease.

New to this subject? Start with our plain-English guide: Treatments →

Study details

• Evidence strengthLow

Read the original

• DOI: 10.1021/acs.jmedchem.7b00393
• PubMed: 28749667
• Original source →

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

@article{prati2018-28749667,
  author  = {Prati, F. and Bottegoni, G. and Bolognesi, M. L. and Cavalli, A.},
  title   = {{BACE-1 Inhibitors: From Recent Single-Target Molecules to Multitarget Compounds for Alzheimer's Disease}},
  journal = {Journal of medicinal chemistry},
  year    = {2018},
  doi     = {10.1021/acs.jmedchem.7b00393},
  pmid    = {28749667},
  url     = {https://doi.org/10.1021/acs.jmedchem.7b00393}
}

Related studies in Treatments

• Acetylcholinesterase inhibitors: novel activities of old molecules Pharmacological research · 2004-10-01 · usefulness score 36/100
• BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer's Disease Pharmaceuticals (Basel, Switzerland) · 2019-03-19 · usefulness score 41/100
• Structural Insights into Curli CsgA Cross-β Fibril Architecture Inspire Repurposing of Anti-amyloid Compounds as Anti-biofilm Agents PLoS pathogens · 2019-08-30 · usefulness score 41/100
• Acetylcholinesterase Enzyme Inhibitor Molecules with Therapeutic Potential for Alzheimer's Disease CNS & neurological disorders drug targets · 2022 · usefulness score 41/100
• Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design International psychogeriatrics · 2015-02-01 · usefulness score 48/100
• Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies Signal transduction and targeted therapy · 2024-08-23 · usefulness score 45/100

Similar studies

• The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans 2015 · Treatments
• The β-Secretase BACE1 in Alzheimer's Disease 2021 · Risk genes beyond APOE
• Recent advances on drug development and emerging therapeutic agents for Alzheimer's disease 2021 · Treatments
• Alzheimer's disease: treatments in discovery and development 2002 · Treatments
• Alzheimer's Disease: Key Insights from Two Decades of Clinical Trial Failures 2022 · Treatments
• Alzheimer's drug-development pipeline: 2016 2016 · Clinical trials

More on Treatments

• A review that covers this ground Amyloid-Related Imaging Abnormalities in the Era of Anti-Amyloid Beta Monoclonal Antibodies for Alzheimer's Disease: Recent Updates on Clinical and Imaging Features and MRI Monitoring Korean journal of radiology · 2024-08-01 · usefulness score 45/100
• Newest in this subject Opposing Regulation of Tau Condensation by Phosphorylation Levels and Molecular Chaperone Interactions bioRxiv · 2026-10-30 · Preprint — not yet peer-reviewed · usefulness score 16/100
• Newest in this subject Natural Sesquiterpenoids from Laggera pterodonta as bioactive Acetylcholinesterase Inhibitors: Insights from DFT, Molecular Docking, and ADMET Profiling Research Square · 2026-10-20 · Preprint — not yet peer-reviewed · usefulness score 16/100

See all studies in Treatments →